Business Wire - Questcor Reports Results of a Phase II Study of Emitasol in Diabetic Gastroparesis
Monday, January 12th, 2009 Business Editors & High Tech Writers
HAYWARD, Calif.–(BUSINESS WIRE)–Oct. 19, 2000
Questcor Pharmaceuticals Inc. (AMEX:QSC) announced today the results of the Phase II study of Emitasol(R) (Metoclopramide, Nasal Spray) in the treatment of diabetic gastroparesis, a serious complication of diabetes that substantially reduces quality of life. The study found encouraging results in terms of safety and a preliminary evaluation of efficacy.
In this open-label, multic…
